Default company panoramic image
Logo

Synergys Biotherapeutics, Inc.

Developing new-generation of multi-targeted and mult-functional anti-vasculogenic antibody therapeutics for cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Walnut Creek, CA, USA
  • Currency USD
  • Founded July 2010
  • Employees 3
  • Website synergysbio.com

Company Summary

Two early stage anti-vasculogenic antibody candidates: (i) Anti-EGFR-ATAP links anti-EGFR MAb to Endostatin-P125A variant as an Antibody-Targeted Anti-vasculogenic Payload (ATAP), for initial development for Triple-Negative Breast Cancer; and, (ii) Anti-Ang-1/2 MAb, is a first-in-class human IgG that targets both Angiopoietin-1 and Angiopoietin-2 for cancer and inflammatory diseases. Bio/pharma companies are our partnering or licensing customers.

Team

  • Default avatar
    Rathin C Das
    Chief Executive Officer

    Over 30 years in Pharma-Biotech, Previously Senior Vice President, Corporate Development and Chief Business officer, Affitech AS , Oslo, Norway and President, Affitech USA, Inc (9 years) , Section Head and Senior level scientist, Bayer Corporation, USA and Bayer AG, Germany ( Combined15 years); Education: PhD, MBA (Executive Program).

  • Default avatar
    Stephen F Carroll
    Senior Vice President, R & D

    More than 20 years in Biotech. Previously Vice President, R&D, Xoma Ltd (16 years), Assistant Professor of Microbiology and Molecular Genetics at Harvard Medical School in Boston, MA; Education: PhD

  • Default avatar
    Linda Pullan
    Vice President, Business Development

    More than 20 years in Bio-pharma. Previously, Vice President, Business Development, Kosan Biosciences, and Director, Oncology and Hematology Business, Amgen; Project Leader, Zeneca; Education: PhD

Advisors

  • Default avatar
    Patrick Rivelli
    Currently, President & CEO, Sonogenix Inc. Previously, Vice President, Strategic Planning, Target Therapeutics, Inc.
    Unconfirmed
    9c4c2335 9ddd 4544 9ee3 f9d8cef869e6
    Currently Managing Partner, Ignatius Transaction Partners, LLC; previously Managing Director, Burrill & Co.
    48e50260 22af 4027 bdca 898e54db53ef
    Currently EVP, Strategic Development atCHA Bio and Diostech Co, Ltd; previously, Vice President, EGeen Inc.
  • Default avatar
    Dr. Bruce Keyt
    Currently CSO, IGM Biosciences, Inc.; previously VP R&D, Abgenix, Genentech.
    Unconfirmed

Previous Investors

  • Default avatar
    Currently Founder-financed.
    Unconfirmed